NCT06091241 ESPBs vs TAPs for Satisfactory Analgesia Following DIEP Surgery
| NCT ID | NCT06091241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2023-11-01 with a primary completion date of 2026-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer is the second most common cancer diagnosed in American women . For patients who have undergone surgical mastectomy, autologous breast reconstruction is an alternative option to breast implants. Deep Inferior Epigastric Perforator (DIEP) flaps are the gold standard for autologous breast reconstruction . Effective pain control following surgery is imperative and ultrasound-guided bilateral transversus abdominis plane blocks (TAPs) with the infiltration of local anesthetics, such a ropivacaine are a common regional technique of choice . A newer described technique, bilateral Erector Spinae Plane blocks (ESPBs) (which also are an infiltration of local anesthetic) present as an alternative approach for post-operative analgesia. ESPBs have been proven efficacious in reducing intra- and post-operative opioid requirements, lessening the need for rescue analgesics in other similar surgical procedures. The hypothesis is that preoperative bilateral ESPBs could provide equivalent pain control as a regional analgesic for patients undergoing DIEP flap surgery when compared to preoperative bilateral TAPs
Eligibility Criteria
Inclusion Criteria: * Adult women with breast cancer, ASA 1-3, undergoing DIEP flap surgery Exclusion Criteria: * Chronic opioid use contraindications to local anesthetics or regional analgesia Inability to communicate intensity of pain on a numeric analog scale
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06091241 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06091241 currently recruiting?
Yes, NCT06091241 is actively recruiting participants. Contact the research team at rkeller@kumc.edu for enrollment information.
Where is the NCT06091241 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT06091241 clinical trial?
NCT06091241 is sponsored by University of Kansas Medical Center. The trial plans to enroll 102 participants.